DrugPatentWatch Database Preview

Drugs in Development Information for CC-223

« Back to Dashboard

Summary for CC-223

US Patents	30
International Patents	316
US Patent Applications	46
WIPO Patent Applications	11
Japanese Patent Applications	0
Clinical Trial Progress	Phase 1 (2010-07-01)
Vendors	27

US Patents for CC-223

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
CC-223		Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines	Signal Pharmaceuticals, LLC (San Diego, CA)
CC-223		Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway	Signal Pharmaceuticals, LLC (San Diego, CA)
CC-223		Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway	Signal Pharmaceuticals, LLC (San Diego, CA)
CC-223		Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway	Signal Pharmaceuticals, LLC (San Diego, CA)
CC-223		Methods of synthesis and purification of heteroaryl compounds	Signal Pharmaceuticals, LLC (San Diego, CA)
CC-223		Methods of synthesis and purification of heteroaryl compounds	Signal Pharmaceuticals, LLC (San Diego, CA)
CC-223		Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors	Signal Pharmaceuticals, LLC (San Diego, CA)

International Patents for CC-223

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
CC-223	European Patent Office	3131552	2034-04-16
CC-223	Japan	2017514806	2034-04-16
CC-223	New Zealand	629860	2034-04-16
CC-223	World Intellectual Property Organization (WIPO)	2015160868	2034-04-16
CC-223	Argentina	073995	2028-10-27
CC-223	Australia	2009320137	2028-10-27
CC-223	Canada	2740975	2028-10-27